Richard J. Robbins, MD

Charles and Anne Duncan Presidential Distinguished Chair, Department of Medicine
Professor of Medicine, Institute for Academic Medicine
Full Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Biography

Dr. Robbins is chairman of the Department of Medicine at Houston Methodist Hospital where he holds the Charles and Anne Duncan Presidential Distinguished Chair in Medicine. He also has an appointments at Weill Medical College of Cornell University and the Institute for Academic Medicine as Professor of Medicine. His current research focuses on defining the natural history, exploring diagnostic strategies, and developing novel diagnostic and targeted therapies for patients with thyroid cancer.

Dr. Robbins is a graduate of the University of Dayton in Ohio, and the Creighton University School of Medicine in Omaha, Nebraska. He received his internal medicine training at The New York Hospital-Cornell Medical Center and completed an Endocrinology fellowship at Tufts-New England Medical Center in Boston. He has held faculty positions at the University of Colorado, Yale Medical School, and came to Houston Methodist from his post as associate chair of medicine for academic affairs, and chief of the endocrine service, at Memorial Sloan Kettering Cancer Center.

Dr. Robbins founded and has served on the board of the Pituitary Society and is the recipient of its Distinguished Service Award. In addition to numerous other awards and honors throughout his career, Dr. Robbins has more than 120 peer-reviewed publications in leading journals such as Nature, Science, and the New England Journal of Medicine. He currently serves on the editorial board of the American Journal of Medicine.

Description of Research

Dr. Robbins has served as principal investigator or co-investigator of multiple basic science studies and clinical trials. His current research focuses on defining the natural history, exploring diagnostic strategies, and developing novel targeted therapies for patients with thyroid carcinoma.

Areas Of Expertise

Thyroid cancer
Education & Training

, Tufts University Medical School
, Weill Cornell Medical College
, Creighton University School of Medicine
Publications

The costs of training internal medicine residents in the United States
Ben-Ari, R, Robbins, RJ, Pindiprolu, S, Goldman, A & Parsons, PE 2014, American Journal of Medicine, vol 127, no. 10, pp. 1017-1023. DOI:

Hürthle cell carcinoma of the thyroid presenting as thyrotoxicosis
Karanchi, H, Hamilton, DJ & Robbins, RJ 2012, Endocrine Practice, vol 18, no. 1. DOI:

Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH
Tala, H, Robbins, R, Fagin, JA, Larson, SM & Tuttle, RM 2011, Journal of Clinical Endocrinology and Metabolism, vol 96, no. 7, pp. 2105-2111. DOI:

The cardiovascular effects of hyperthyroidism.
Nabbout, LA & Robbins, RJ 2010, Houston Methodist DeBakey Cardiovascular Journal, vol 6, no. 2, pp. 3-8.

Reply: A new age for recombinant human thyroid-stimulating hormone?
Tuttle, RM, Robbins, RJ, Brokhin, M & Larson, SM 2009, Journal of Nuclear Medicine, vol 50, no. 5, pp. 832-833. DOI:

The value of positron emission tomography (PET) in the management of patients with thyroid cancer
Robbins, RJ & Larson, SM 2008, Best Practice and Research: Clinical Endocrinology and Metabolism, vol 22, no. 6, pp. 1047-1059. DOI:

Expanding indications for recombinant human TSH in thyroid cancer
Haugen, BR, Cooper, DS, Emerson, CH, Luster, M, Maciel, RMB, Biscolla, RPM, Mazzaferri, EL, Medeiros-Neto, G, Reiners, C, Robbins, RJ, Robinson, BG, Schlumberger, M, Yamashita, S & Pacini, F 2008, Thyroid, vol 18, no. 7, pp. 687-694. DOI:

Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal
Tuttle, RM, Brokhin, M, Omry, G, Martorella, AJ, Larson, SM, Grewal, RK, Fleisher, M & Robbins, RJ 2008, Journal of Nuclear Medicine, vol 49, no. 5, pp. 764-770. DOI:

A sequence-specific exopeptidase activity test (SSEAT) for "functional" biomarker discovery
Villanueva, J, Nazarian, A, Lawlor, K, Yi, SS, Robbins, RJ & Tempst, P 2008, Molecular and Cellular Proteomics, vol 7, no. 3, pp. 509-518. DOI:

Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib [3]
Feldman, DR, Martorella, AJ, Robbins, RJ & Motzer, RJ 2007, Journal of the National Cancer Institute, vol 99, no. 12, pp. 974-975. DOI:

Serum peptide profiling: Identifying novel cancer biomarkers for early disease detection
Martorella, A & Robbins, R 2007, Acta Biomedica, vol 78, no. SUPPL. 1, pp. 123-128.

Radioiodine dosimetry with recombinant human thyrotropin
Tuttle, RM & Robbins, RJ 2006, . in Thyroid Cancer (Second Edition): A Comprehensive Guide to Clinical Management. Humana Press, pp. 447-451. DOI:

131I treatment of metastatic thyroid carcinoma following preparation by recombinant human thyrotropin
Robbins, RJ & Tuttle, RM 2006, . in Thyroid Cancer (Second Edition): A Comprehensive Guide to Clinical Management. Humana Press, pp. 427-431. DOI:

Chapter 6 The role of fluoro-deoxy glucose (FDG) positron emission tomography (PET) in the management of differentiated thyroid cancer
Robbins, RJ, Chan, CY, Tuttle, RM & Larson, SM 2006, Advances in Molecular and Cellular Endocrinology, vol 4, no. C, pp. 107-116. DOI:

Thyroid remnant radioiodine ablation with recombinant human thyrotropin
Tuttle, RM & Robbins, RJ 2006, . in Thyroid Cancer (Second Edition): A Comprehensive Guide to Clinical Management. Humana Press, pp. 283-286. DOI:

Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine
Robbins, RJ, Driedger, A & Magner, J 2006, Thyroid, vol 16, no. 11, pp. 1121-1130. DOI:

Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age
Villanueva, J, Martorella, AJ, Lawlor, K, Philip, J, Fleisher, M, Robbins, RJ & Tempst, P 2006, Molecular and Cellular Proteomics, vol 5, no. 10, pp. 1840-1852. DOI:

Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer
Tuttle, RM, Leboeuf, R, Robbins, RJ, Qualey, R, Pentlow, K, Larson, SM & Chan, CY 2006, Journal of Nuclear Medicine, vol 47, no. 10, pp. 1587-1591.

Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients
Pryma, DA, Schöder, H, Gönen, M, Robbins, RJ, Larson, SM & Yeung, HWD 2006, Journal of Nuclear Medicine, vol 47, no. 8, pp. 1260-1266.

Real-time prognosis for metastatic thyroid carcinoma based on 2-[ 18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning
Robbins, RJ, Wan, Q, Grewal, RK, Reibke, R, Gonen, M, Strauss, HW, Tuttle, RM, Drucker, W & Larson, SM 2006, Journal of Clinical Endocrinology and Metabolism, vol 91, no. 2, pp. 498-505. DOI: